Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Core Insights - Xencor, Inc. is a clinical-stage biopharmaceutical company focused on developing engineered antibodies for cancer and autoimmune diseases [1] - The company announced the upcoming presentation of initial results from a Phase 1 dose-escalation study of XmAb819, a bispecific antibody targeting ENPP3 and CD3, specifically in patients with clear cell renal cell carcinoma (ccRCC) [1] Company Overview - Xencor, Inc. is listed on NASDAQ under the ticker XNCR [1] - The company specializes in engineered antibodies, which are designed to treat various medical conditions, including cancer and autoimmune diseases [1] Study Details - The Phase 1 dose-escalation study focuses on XmAb819, which is a bispecific T-cell engaging antibody [1] - Initial results from this study will be presented at the AACR-NCI-EORTC Conference on Molecular Targets [1]